| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -22.3 | 45.4 |
| EPS (diluted, $ a share) | $-0.24 | $-0.21 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: SABS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
SAB Biotherapeutics, Inc.: key numbers
- Share price
- $3.00Close, Nov 16
- Market cap
- $270M
- Shares outstanding
- 90.09MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from SAB Biotherapeutics, Inc.
All →SAB Biotherapeutics Regulatory Approval
SAB Biotherapeutics announced that the FDA has granted Fast Track designation to SAB-142, a fully human anti-thymocyte immunoglobulin being developed for Stage 3 type 1 diabetes. The designation is intended to expedite the development and review of the immunotherapy, which is currently in a Phase 2b clinical trial. Topline data from the SAFEGUARD study is anticipated in the second half of 2027.